20th Jun 2016 06:41
LONDON (Alliance News) - Hutchison China MediTech Ltd on Monday said it has initiated a phase-two expansion of its ongoing trial evaluating selective c-Met inhibitor savolitinib for non-small cell lung cancer.
The expansion of the trial follows encouraging early data from patients enrolled in the study.
The expansion will also trigger a USD10.0 million milestone payment to Hutchison from AstraZeneca PLC, the UK drugmaker.
"We believe that savolitinib either as a monotherapy in first-line NSCLC, or in proprietary combinations with AstraZeneca's Iressa and Tagrisso in second- and third-line NSCLC, will address the key genetic drivers of cancer cell proliferation in these very difficult-to-treat NSCLC patients. We are hopeful about proceeding into Phase III in 2017 based on future data from this study," said Christian Hogg, Hutchison's chief executive.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
AstrazenecaHutchmed